Adiponectin, leptin, nitric oxide, and C-reactive protein levels in kidney transplant recipients: comparison with the hemodialysis and chronic renal failure

Figures & data

Table 1. Demographic and clinical characteristics of kidney transplant recipients, patients with chronic renal failure, hemodialysis patients, and the control group.

	Control	CRF	HD	KTR
Age (years)	34 ± 7	42 ± 13^a^,^d	31 ± 8^b^,^d	36 ± 10^b^,^d^,^c^,^d
Male/female	10/8	10/8	9/9	9/9
BMI (kg/m^2)	24.6 ± 4.4	24.5 ± 5.1	21.7 ± 6.9^a^,^d^,^b^,^d	26.2 ± 4.5^b^,^e^,^c^,^d
Hypertension	0 (0%)	12 (66%)^a^,^e	3 (17%)^b^,^e	11 (61%)^a^,^e^,^c^,^d
Smokers	7 (38%)	4 (22%)	4 (22%)	4 (22%)
Duration of disease/HD/Post-Tx (months)	–	49 ± 41	85 ± 51	57 ± 50

Data are provided as means ± standard deviations or n (%).

KTR: kidney transplant recipients; BMI: body mass index; Post-Tx: post-transplantation.

a vs. controls.

b vs. chronic renal failure (CRF).

c vs. hemodialysis (HD).

d p < .05.

e p < .01.

Table 2. Biochemical characteristics (mg/dL) of the groups.

	Control	CRF	HD	KTR
Urea	28 ± 7	98 ± 51^a^,^e	124 ± 21^a^,^e^,^b^,^d	40 ± 16^a^,^d^,^c^,^e
Creatinine	0.9 ± 0.1	2.4 ± 1.1^a^,^e	8.7 ± 1.9^a^,^e^,^b^,^e	1.3 ± 0.3^a^,^e^,^c^,^e
TC	185 ± 89	216 ± 55	157 ± 85^a^,^d^,^b^,^e	206 ± 51^c^,^d
TG	122 ± 72	197 ± 92^a^,^d	151 ± 81	176 ± 83^a^,^d
LDL-C	109 ± 82	128 ± 40	83 ± 22^a^,^d^,^b^,^d	125 ± 40^c^,^e
HDL-C	53 ± 14	57 ± 28	40 ± 9^a^,^d^,^b^,^d	48 ± 10^c^,^d
Apo A1	114 ± 31	126 ± 25	101 ± 24^b^,^d	125 ± 19^c^,^d
Apo B	77 ± 26	125 ± 43^a^,e	76 ± 22^b^,e	92 ± 25^b^,d,^c^,d
Lp (a)	12.5 (2–39)	48.0^a^,^d (13.3–114.8)	14.0 (8.5–60.5)	4.5^b^,^d (1.8–45)

Data are given as means ± standard deviations or as medians (interquartile ranges 25–75%).

KTR: kidney transplant recipients; TC: total cholesterol; TG: triglycerides; LDL-C: low density lipoprotein-cholesterol; HDL-C: high density lipoprotein-cholesterol; Apo A1: apolipoprotein A1; Apo B: apolipoprotein B; Lp (a): lipoprotein (a).

a vs. controls.

b vs. chronic renal failure (CRF).

c vs. hemodialysis (HD).

d p < .05.

e p < .01.

Table 3. Serum concentrations of nitric oxide, adiponectin, leptin, and hs-CRP in the control subjects and the patient groups.

	Control	CRF	HD	KTR
Nitric oxide, μmol/L	15.3 ± 18.4	26.9 ± 16.6^a^,^c	42.2 ± 26.1^a^,^d	43.7 ± 28.9^a^,d,^b^,^c
Adiponectin, μg/mL	6.8 ± 4.9	16.4 ± 10.7^a^,^d	14.8 ± 7.1^a^,^d	14.4 ± 6.9^a^,^d
Leptin, ng/mL	6.9 ± 4.2	24.1 ± 34.1	26.3 ± 35.8	22.9 ± 20.4^a^,^d
hs-CRP, mg/dL	0.16 ± 0.17	0.33 ± 0.32	1.09 ± 1.74^a^,^d^,^b^,^c	0.52 ± 0.81^a^,^c

Data are given as means ± standard deviations.

a vs. controls.

b vs. chronic renal failure (CRF).

c p < .05.

d p < .01.